PDCD1 and non-small cell lung carcinoma: In the context of NSCLC patients at the moment of response to anti-PD-1 treatment, a reduction of the number of clonal mutations and T cell repertoire evenness is proportional to the response, being 19% the average fraction of remaining variants in those patients with complete and partial response, and 101% the fraction for patients presenting disease progression [73].